nodes	percent_of_prediction	percent_of_DWPC	metapath
Zaleplon—CYP3A7-CYP3A51P—Paclitaxel—ovarian cancer	0.0823	0.156	CbGbCtD
Zaleplon—CYP3A7—Paclitaxel—ovarian cancer	0.0823	0.156	CbGbCtD
Zaleplon—CYP3A5—Paclitaxel—ovarian cancer	0.0617	0.117	CbGbCtD
Zaleplon—CYP3A7-CYP3A51P—Docetaxel—ovarian cancer	0.0595	0.113	CbGbCtD
Zaleplon—CYP3A7—Docetaxel—ovarian cancer	0.0595	0.113	CbGbCtD
Zaleplon—CYP3A4—Topotecan—ovarian cancer	0.0486	0.0922	CbGbCtD
Zaleplon—CYP3A5—Docetaxel—ovarian cancer	0.0446	0.0847	CbGbCtD
Zaleplon—CYP3A4—Vinorelbine—ovarian cancer	0.0343	0.065	CbGbCtD
Zaleplon—CYP3A4—Paclitaxel—ovarian cancer	0.0241	0.0457	CbGbCtD
Zaleplon—CYP3A4—Docetaxel—ovarian cancer	0.0174	0.033	CbGbCtD
Zaleplon—CYP3A4—Doxorubicin—ovarian cancer	0.013	0.0246	CbGbCtD
Zaleplon—TSPO—oviduct—ovarian cancer	0.00827	0.125	CbGeAlD
Zaleplon—AOX1—myometrium—ovarian cancer	0.0031	0.0468	CbGeAlD
Zaleplon—TSPO—myometrium—ovarian cancer	0.00265	0.04	CbGeAlD
Zaleplon—TSPO—embryo—ovarian cancer	0.00254	0.0384	CbGeAlD
Zaleplon—AOX1—uterine cervix—ovarian cancer	0.00241	0.0364	CbGeAlD
Zaleplon—AOX1—decidua—ovarian cancer	0.0023	0.0347	CbGeAlD
Zaleplon—AOX1—endometrium—ovarian cancer	0.00218	0.0329	CbGeAlD
Zaleplon—TSPO—epithelium—ovarian cancer	0.00208	0.0314	CbGeAlD
Zaleplon—TSPO—uterine cervix—ovarian cancer	0.00206	0.0311	CbGeAlD
Zaleplon—AOX1—gonad—ovarian cancer	0.00202	0.0305	CbGeAlD
Zaleplon—AOX1—uterus—ovarian cancer	0.00201	0.0303	CbGeAlD
Zaleplon—TSPO—decidua—ovarian cancer	0.00196	0.0296	CbGeAlD
Zaleplon—TSPO—endometrium—ovarian cancer	0.00186	0.0281	CbGeAlD
Zaleplon—AOX1—female reproductive system—ovarian cancer	0.00181	0.0273	CbGeAlD
Zaleplon—TSPO—gonad—ovarian cancer	0.00173	0.0261	CbGeAlD
Zaleplon—TSPO—uterus—ovarian cancer	0.00172	0.0259	CbGeAlD
Zaleplon—AOX1—female gonad—ovarian cancer	0.00164	0.0248	CbGeAlD
Zaleplon—AOX1—vagina—ovarian cancer	0.00163	0.0247	CbGeAlD
Zaleplon—GABRB3—gonad—ovarian cancer	0.00157	0.0237	CbGeAlD
Zaleplon—TSPO—female reproductive system—ovarian cancer	0.00154	0.0233	CbGeAlD
Zaleplon—GABRA2—vagina—ovarian cancer	0.00151	0.0228	CbGeAlD
Zaleplon—GABRB2—testis—ovarian cancer	0.00147	0.0222	CbGeAlD
Zaleplon—AOX1—testis—ovarian cancer	0.00146	0.022	CbGeAlD
Zaleplon—TSPO—bone marrow—ovarian cancer	0.00146	0.022	CbGeAlD
Zaleplon—TSPO—female gonad—ovarian cancer	0.0014	0.0212	CbGeAlD
Zaleplon—GABRB3—female reproductive system—ovarian cancer	0.0014	0.0212	CbGeAlD
Zaleplon—TSPO—vagina—ovarian cancer	0.00139	0.0211	CbGeAlD
Zaleplon—CYP3A5—uterine cervix—ovarian cancer	0.00127	0.0193	CbGeAlD
Zaleplon—TSPO—testis—ovarian cancer	0.00124	0.0188	CbGeAlD
Zaleplon—GABRB3—testis—ovarian cancer	0.00113	0.0171	CbGeAlD
Zaleplon—AOX1—lymph node—ovarian cancer	0.00106	0.016	CbGeAlD
Zaleplon—GABRA2—lymph node—ovarian cancer	0.000975	0.0147	CbGeAlD
Zaleplon—TSPO—lymph node—ovarian cancer	0.000902	0.0136	CbGeAlD
Zaleplon—CYP3A5—female gonad—ovarian cancer	0.000869	0.0131	CbGeAlD
Zaleplon—CYP3A5—vagina—ovarian cancer	0.000864	0.0131	CbGeAlD
Zaleplon—CYP3A4—female reproductive system—ovarian cancer	0.000717	0.0108	CbGeAlD
Zaleplon—Confusional state—Paclitaxel—ovarian cancer	0.000299	0.000736	CcSEcCtD
Zaleplon—Asthma—Epirubicin—ovarian cancer	0.000298	0.000734	CcSEcCtD
Zaleplon—Dysphagia—Epirubicin—ovarian cancer	0.000298	0.000734	CcSEcCtD
Zaleplon—Back pain—Docetaxel—ovarian cancer	0.000298	0.000733	CcSEcCtD
Zaleplon—Oedema—Paclitaxel—ovarian cancer	0.000297	0.00073	CcSEcCtD
Zaleplon—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000297	0.00073	CcSEcCtD
Zaleplon—Eosinophilia—Epirubicin—ovarian cancer	0.000295	0.000726	CcSEcCtD
Zaleplon—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000295	0.000725	CcSEcCtD
Zaleplon—Dry skin—Doxorubicin—ovarian cancer	0.000293	0.00072	CcSEcCtD
Zaleplon—Shock—Paclitaxel—ovarian cancer	0.000292	0.000718	CcSEcCtD
Zaleplon—Dizziness—Vinorelbine—ovarian cancer	0.000292	0.000718	CcSEcCtD
Zaleplon—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000292	0.000717	CcSEcCtD
Zaleplon—Nervous system disorder—Paclitaxel—ovarian cancer	0.000291	0.000716	CcSEcCtD
Zaleplon—Angina pectoris—Epirubicin—ovarian cancer	0.000291	0.000715	CcSEcCtD
Zaleplon—Tachycardia—Paclitaxel—ovarian cancer	0.00029	0.000712	CcSEcCtD
Zaleplon—Breast disorder—Doxorubicin—ovarian cancer	0.000289	0.00071	CcSEcCtD
Zaleplon—Skin disorder—Paclitaxel—ovarian cancer	0.000288	0.000709	CcSEcCtD
Zaleplon—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000288	0.000707	CcSEcCtD
Zaleplon—Bronchitis—Epirubicin—ovarian cancer	0.000287	0.000706	CcSEcCtD
Zaleplon—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000287	0.000706	CcSEcCtD
Zaleplon—Anaemia—Docetaxel—ovarian cancer	0.000285	0.000701	CcSEcCtD
Zaleplon—Anorexia—Paclitaxel—ovarian cancer	0.000283	0.000696	CcSEcCtD
Zaleplon—Gastritis—Doxorubicin—ovarian cancer	0.000283	0.000695	CcSEcCtD
Zaleplon—Muscular weakness—Doxorubicin—ovarian cancer	0.000282	0.000693	CcSEcCtD
Zaleplon—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000282	0.000693	CcSEcCtD
Zaleplon—Dysuria—Epirubicin—ovarian cancer	0.000279	0.000686	CcSEcCtD
Zaleplon—Rash—Vinorelbine—ovarian cancer	0.000278	0.000684	CcSEcCtD
Zaleplon—Dermatitis—Vinorelbine—ovarian cancer	0.000278	0.000684	CcSEcCtD
Zaleplon—Hypotension—Paclitaxel—ovarian cancer	0.000277	0.000682	CcSEcCtD
Zaleplon—Headache—Vinorelbine—ovarian cancer	0.000276	0.00068	CcSEcCtD
Zaleplon—Syncope—Docetaxel—ovarian cancer	0.000276	0.00068	CcSEcCtD
Zaleplon—Asthma—Doxorubicin—ovarian cancer	0.000276	0.000679	CcSEcCtD
Zaleplon—Dysphagia—Doxorubicin—ovarian cancer	0.000276	0.000679	CcSEcCtD
Zaleplon—Pollakiuria—Epirubicin—ovarian cancer	0.000276	0.000678	CcSEcCtD
Zaleplon—Eosinophilia—Doxorubicin—ovarian cancer	0.000273	0.000672	CcSEcCtD
Zaleplon—Palpitations—Docetaxel—ovarian cancer	0.000272	0.00067	CcSEcCtD
Zaleplon—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000272	0.00067	CcSEcCtD
Zaleplon—Weight increased—Epirubicin—ovarian cancer	0.000271	0.000668	CcSEcCtD
Zaleplon—Loss of consciousness—Docetaxel—ovarian cancer	0.000271	0.000666	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00027	0.000665	CcSEcCtD
Zaleplon—Weight decreased—Epirubicin—ovarian cancer	0.00027	0.000664	CcSEcCtD
Zaleplon—Hyperglycaemia—Epirubicin—ovarian cancer	0.000269	0.000662	CcSEcCtD
Zaleplon—Angina pectoris—Doxorubicin—ovarian cancer	0.000269	0.000661	CcSEcCtD
Zaleplon—Insomnia—Paclitaxel—ovarian cancer	0.000268	0.00066	CcSEcCtD
Zaleplon—Pneumonia—Epirubicin—ovarian cancer	0.000267	0.000658	CcSEcCtD
Zaleplon—Paraesthesia—Paclitaxel—ovarian cancer	0.000266	0.000655	CcSEcCtD
Zaleplon—Hypertension—Docetaxel—ovarian cancer	0.000266	0.000654	CcSEcCtD
Zaleplon—Bronchitis—Doxorubicin—ovarian cancer	0.000265	0.000653	CcSEcCtD
Zaleplon—Dyspnoea—Paclitaxel—ovarian cancer	0.000264	0.000651	CcSEcCtD
Zaleplon—Somnolence—Paclitaxel—ovarian cancer	0.000264	0.000649	CcSEcCtD
Zaleplon—Myalgia—Docetaxel—ovarian cancer	0.000262	0.000645	CcSEcCtD
Zaleplon—Chest pain—Docetaxel—ovarian cancer	0.000262	0.000645	CcSEcCtD
Zaleplon—Arthralgia—Docetaxel—ovarian cancer	0.000262	0.000645	CcSEcCtD
Zaleplon—Nausea—Vinorelbine—ovarian cancer	0.000262	0.000645	CcSEcCtD
Zaleplon—Dyspepsia—Paclitaxel—ovarian cancer	0.000261	0.000642	CcSEcCtD
Zaleplon—Neuropathy peripheral—Epirubicin—ovarian cancer	0.000261	0.000641	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000261	0.000641	CcSEcCtD
Zaleplon—Stomatitis—Epirubicin—ovarian cancer	0.000259	0.000638	CcSEcCtD
Zaleplon—Conjunctivitis—Epirubicin—ovarian cancer	0.000258	0.000636	CcSEcCtD
Zaleplon—Dysuria—Doxorubicin—ovarian cancer	0.000258	0.000635	CcSEcCtD
Zaleplon—Decreased appetite—Paclitaxel—ovarian cancer	0.000258	0.000634	CcSEcCtD
Zaleplon—Dry mouth—Docetaxel—ovarian cancer	0.000257	0.000631	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000256	0.00063	CcSEcCtD
Zaleplon—Sweating—Epirubicin—ovarian cancer	0.000255	0.000627	CcSEcCtD
Zaleplon—Pollakiuria—Doxorubicin—ovarian cancer	0.000255	0.000627	CcSEcCtD
Zaleplon—Pain—Paclitaxel—ovarian cancer	0.000254	0.000624	CcSEcCtD
Zaleplon—Constipation—Paclitaxel—ovarian cancer	0.000254	0.000624	CcSEcCtD
Zaleplon—Haematuria—Epirubicin—ovarian cancer	0.000254	0.000624	CcSEcCtD
Zaleplon—Confusional state—Docetaxel—ovarian cancer	0.000254	0.000624	CcSEcCtD
Zaleplon—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.000252	0.00062	CcSEcCtD
Zaleplon—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000252	0.000619	CcSEcCtD
Zaleplon—Anaphylactic shock—Docetaxel—ovarian cancer	0.000251	0.000619	CcSEcCtD
Zaleplon—Oedema—Docetaxel—ovarian cancer	0.000251	0.000619	CcSEcCtD
Zaleplon—Weight increased—Doxorubicin—ovarian cancer	0.000251	0.000618	CcSEcCtD
Zaleplon—Epistaxis—Epirubicin—ovarian cancer	0.000251	0.000617	CcSEcCtD
Zaleplon—Weight decreased—Doxorubicin—ovarian cancer	0.00025	0.000614	CcSEcCtD
Zaleplon—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000249	0.000612	CcSEcCtD
Zaleplon—Pneumonia—Doxorubicin—ovarian cancer	0.000247	0.000609	CcSEcCtD
Zaleplon—Shock—Docetaxel—ovarian cancer	0.000247	0.000609	CcSEcCtD
Zaleplon—Nervous system disorder—Docetaxel—ovarian cancer	0.000247	0.000607	CcSEcCtD
Zaleplon—Tachycardia—Docetaxel—ovarian cancer	0.000245	0.000604	CcSEcCtD
Zaleplon—Feeling abnormal—Paclitaxel—ovarian cancer	0.000244	0.000601	CcSEcCtD
Zaleplon—Skin disorder—Docetaxel—ovarian cancer	0.000244	0.000601	CcSEcCtD
Zaleplon—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000243	0.000597	CcSEcCtD
Zaleplon—Neuropathy peripheral—Doxorubicin—ovarian cancer	0.000241	0.000593	CcSEcCtD
Zaleplon—Stomatitis—Doxorubicin—ovarian cancer	0.00024	0.00059	CcSEcCtD
Zaleplon—Anorexia—Docetaxel—ovarian cancer	0.00024	0.00059	CcSEcCtD
Zaleplon—Conjunctivitis—Doxorubicin—ovarian cancer	0.000239	0.000588	CcSEcCtD
Zaleplon—Hypoaesthesia—Epirubicin—ovarian cancer	0.000238	0.000584	CcSEcCtD
Zaleplon—Sweating—Doxorubicin—ovarian cancer	0.000236	0.00058	CcSEcCtD
Zaleplon—Urticaria—Paclitaxel—ovarian cancer	0.000236	0.00058	CcSEcCtD
Zaleplon—Oedema peripheral—Epirubicin—ovarian cancer	0.000235	0.000579	CcSEcCtD
Zaleplon—Hypotension—Docetaxel—ovarian cancer	0.000235	0.000578	CcSEcCtD
Zaleplon—Haematuria—Doxorubicin—ovarian cancer	0.000235	0.000577	CcSEcCtD
Zaleplon—Abdominal pain—Paclitaxel—ovarian cancer	0.000235	0.000577	CcSEcCtD
Zaleplon—Body temperature increased—Paclitaxel—ovarian cancer	0.000235	0.000577	CcSEcCtD
Zaleplon—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000233	0.000573	CcSEcCtD
Zaleplon—Epistaxis—Doxorubicin—ovarian cancer	0.000232	0.000571	CcSEcCtD
Zaleplon—Visual impairment—Epirubicin—ovarian cancer	0.00023	0.000566	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000229	0.000564	CcSEcCtD
Zaleplon—Insomnia—Docetaxel—ovarian cancer	0.000227	0.00056	CcSEcCtD
Zaleplon—Paraesthesia—Docetaxel—ovarian cancer	0.000226	0.000555	CcSEcCtD
Zaleplon—Dyspnoea—Docetaxel—ovarian cancer	0.000224	0.000552	CcSEcCtD
Zaleplon—Somnolence—Docetaxel—ovarian cancer	0.000224	0.00055	CcSEcCtD
Zaleplon—Eye disorder—Epirubicin—ovarian cancer	0.000223	0.000549	CcSEcCtD
Zaleplon—Tinnitus—Epirubicin—ovarian cancer	0.000223	0.000548	CcSEcCtD
Zaleplon—Dyspepsia—Docetaxel—ovarian cancer	0.000221	0.000545	CcSEcCtD
Zaleplon—Hypoaesthesia—Doxorubicin—ovarian cancer	0.00022	0.000541	CcSEcCtD
Zaleplon—Decreased appetite—Docetaxel—ovarian cancer	0.000219	0.000538	CcSEcCtD
Zaleplon—Oedema peripheral—Doxorubicin—ovarian cancer	0.000218	0.000535	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000217	0.000534	CcSEcCtD
Zaleplon—Immune system disorder—Epirubicin—ovarian cancer	0.000216	0.00053	CcSEcCtD
Zaleplon—Constipation—Docetaxel—ovarian cancer	0.000215	0.000529	CcSEcCtD
Zaleplon—Pain—Docetaxel—ovarian cancer	0.000215	0.000529	CcSEcCtD
Zaleplon—Chills—Epirubicin—ovarian cancer	0.000214	0.000527	CcSEcCtD
Zaleplon—Visual impairment—Doxorubicin—ovarian cancer	0.000213	0.000524	CcSEcCtD
Zaleplon—Asthenia—Paclitaxel—ovarian cancer	0.000213	0.000524	CcSEcCtD
Zaleplon—Alopecia—Epirubicin—ovarian cancer	0.000211	0.000519	CcSEcCtD
Zaleplon—Pruritus—Paclitaxel—ovarian cancer	0.00021	0.000516	CcSEcCtD
Zaleplon—Mental disorder—Epirubicin—ovarian cancer	0.000209	0.000515	CcSEcCtD
Zaleplon—Malnutrition—Epirubicin—ovarian cancer	0.000208	0.000511	CcSEcCtD
Zaleplon—Feeling abnormal—Docetaxel—ovarian cancer	0.000207	0.00051	CcSEcCtD
Zaleplon—Eye disorder—Doxorubicin—ovarian cancer	0.000206	0.000508	CcSEcCtD
Zaleplon—Tinnitus—Doxorubicin—ovarian cancer	0.000206	0.000507	CcSEcCtD
Zaleplon—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000206	0.000506	CcSEcCtD
Zaleplon—Flatulence—Epirubicin—ovarian cancer	0.000205	0.000504	CcSEcCtD
Zaleplon—Tension—Epirubicin—ovarian cancer	0.000204	0.000502	CcSEcCtD
Zaleplon—Dysgeusia—Epirubicin—ovarian cancer	0.000204	0.000501	CcSEcCtD
Zaleplon—Nervousness—Epirubicin—ovarian cancer	0.000202	0.000497	CcSEcCtD
Zaleplon—Back pain—Epirubicin—ovarian cancer	0.000201	0.000495	CcSEcCtD
Zaleplon—Immune system disorder—Doxorubicin—ovarian cancer	0.0002	0.000491	CcSEcCtD
Zaleplon—Abdominal pain—Docetaxel—ovarian cancer	0.000199	0.000489	CcSEcCtD
Zaleplon—Body temperature increased—Docetaxel—ovarian cancer	0.000199	0.000489	CcSEcCtD
Zaleplon—Chills—Doxorubicin—ovarian cancer	0.000198	0.000488	CcSEcCtD
Zaleplon—Dizziness—Paclitaxel—ovarian cancer	0.000196	0.000483	CcSEcCtD
Zaleplon—Alopecia—Doxorubicin—ovarian cancer	0.000195	0.00048	CcSEcCtD
Zaleplon—Mental disorder—Doxorubicin—ovarian cancer	0.000194	0.000476	CcSEcCtD
Zaleplon—Ill-defined disorder—Epirubicin—ovarian cancer	0.000193	0.000474	CcSEcCtD
Zaleplon—Malnutrition—Doxorubicin—ovarian cancer	0.000192	0.000473	CcSEcCtD
Zaleplon—Anaemia—Epirubicin—ovarian cancer	0.000192	0.000473	CcSEcCtD
Zaleplon—Agitation—Epirubicin—ovarian cancer	0.000191	0.00047	CcSEcCtD
Zaleplon—Flatulence—Doxorubicin—ovarian cancer	0.000189	0.000466	CcSEcCtD
Zaleplon—Tension—Doxorubicin—ovarian cancer	0.000189	0.000464	CcSEcCtD
Zaleplon—Dysgeusia—Doxorubicin—ovarian cancer	0.000188	0.000463	CcSEcCtD
Zaleplon—Malaise—Epirubicin—ovarian cancer	0.000187	0.000461	CcSEcCtD
Zaleplon—Rash—Paclitaxel—ovarian cancer	0.000187	0.00046	CcSEcCtD
Zaleplon—Dermatitis—Paclitaxel—ovarian cancer	0.000187	0.00046	CcSEcCtD
Zaleplon—Nervousness—Doxorubicin—ovarian cancer	0.000187	0.000459	CcSEcCtD
Zaleplon—Vertigo—Epirubicin—ovarian cancer	0.000187	0.000459	CcSEcCtD
Zaleplon—Syncope—Epirubicin—ovarian cancer	0.000186	0.000458	CcSEcCtD
Zaleplon—Back pain—Doxorubicin—ovarian cancer	0.000186	0.000458	CcSEcCtD
Zaleplon—Headache—Paclitaxel—ovarian cancer	0.000186	0.000457	CcSEcCtD
Zaleplon—Palpitations—Epirubicin—ovarian cancer	0.000184	0.000452	CcSEcCtD
Zaleplon—Loss of consciousness—Epirubicin—ovarian cancer	0.000183	0.000449	CcSEcCtD
Zaleplon—Asthenia—Docetaxel—ovarian cancer	0.00018	0.000444	CcSEcCtD
Zaleplon—Hypertension—Epirubicin—ovarian cancer	0.000179	0.000441	CcSEcCtD
Zaleplon—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000178	0.000439	CcSEcCtD
Zaleplon—Pruritus—Docetaxel—ovarian cancer	0.000178	0.000438	CcSEcCtD
Zaleplon—Anaemia—Doxorubicin—ovarian cancer	0.000178	0.000437	CcSEcCtD
Zaleplon—Chest pain—Epirubicin—ovarian cancer	0.000177	0.000435	CcSEcCtD
Zaleplon—Arthralgia—Epirubicin—ovarian cancer	0.000177	0.000435	CcSEcCtD
Zaleplon—Myalgia—Epirubicin—ovarian cancer	0.000177	0.000435	CcSEcCtD
Zaleplon—Agitation—Doxorubicin—ovarian cancer	0.000177	0.000435	CcSEcCtD
Zaleplon—Anxiety—Epirubicin—ovarian cancer	0.000176	0.000434	CcSEcCtD
Zaleplon—Nausea—Paclitaxel—ovarian cancer	0.000176	0.000434	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000176	0.000432	CcSEcCtD
Zaleplon—Discomfort—Epirubicin—ovarian cancer	0.000175	0.00043	CcSEcCtD
Zaleplon—Malaise—Doxorubicin—ovarian cancer	0.000173	0.000427	CcSEcCtD
Zaleplon—Dry mouth—Epirubicin—ovarian cancer	0.000173	0.000426	CcSEcCtD
Zaleplon—Vertigo—Doxorubicin—ovarian cancer	0.000173	0.000425	CcSEcCtD
Zaleplon—Syncope—Doxorubicin—ovarian cancer	0.000172	0.000424	CcSEcCtD
Zaleplon—Confusional state—Epirubicin—ovarian cancer	0.000171	0.000421	CcSEcCtD
Zaleplon—Palpitations—Doxorubicin—ovarian cancer	0.00017	0.000418	CcSEcCtD
Zaleplon—Anaphylactic shock—Epirubicin—ovarian cancer	0.00017	0.000417	CcSEcCtD
Zaleplon—Oedema—Epirubicin—ovarian cancer	0.00017	0.000417	CcSEcCtD
Zaleplon—Loss of consciousness—Doxorubicin—ovarian cancer	0.000169	0.000416	CcSEcCtD
Zaleplon—Shock—Epirubicin—ovarian cancer	0.000167	0.000411	CcSEcCtD
Zaleplon—Nervous system disorder—Epirubicin—ovarian cancer	0.000166	0.000409	CcSEcCtD
Zaleplon—Dizziness—Docetaxel—ovarian cancer	0.000166	0.000409	CcSEcCtD
Zaleplon—Hypertension—Doxorubicin—ovarian cancer	0.000166	0.000408	CcSEcCtD
Zaleplon—Tachycardia—Epirubicin—ovarian cancer	0.000166	0.000407	CcSEcCtD
Zaleplon—Skin disorder—Epirubicin—ovarian cancer	0.000165	0.000405	CcSEcCtD
Zaleplon—Hyperhidrosis—Epirubicin—ovarian cancer	0.000164	0.000403	CcSEcCtD
Zaleplon—Chest pain—Doxorubicin—ovarian cancer	0.000164	0.000403	CcSEcCtD
Zaleplon—Myalgia—Doxorubicin—ovarian cancer	0.000164	0.000403	CcSEcCtD
Zaleplon—Arthralgia—Doxorubicin—ovarian cancer	0.000164	0.000403	CcSEcCtD
Zaleplon—Anxiety—Doxorubicin—ovarian cancer	0.000163	0.000401	CcSEcCtD
Zaleplon—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000163	0.0004	CcSEcCtD
Zaleplon—Discomfort—Doxorubicin—ovarian cancer	0.000162	0.000398	CcSEcCtD
Zaleplon—Anorexia—Epirubicin—ovarian cancer	0.000162	0.000398	CcSEcCtD
Zaleplon—Dry mouth—Doxorubicin—ovarian cancer	0.00016	0.000394	CcSEcCtD
Zaleplon—Rash—Docetaxel—ovarian cancer	0.000159	0.00039	CcSEcCtD
Zaleplon—Hypotension—Epirubicin—ovarian cancer	0.000158	0.00039	CcSEcCtD
Zaleplon—Dermatitis—Docetaxel—ovarian cancer	0.000158	0.00039	CcSEcCtD
Zaleplon—Confusional state—Doxorubicin—ovarian cancer	0.000158	0.000389	CcSEcCtD
Zaleplon—Headache—Docetaxel—ovarian cancer	0.000158	0.000388	CcSEcCtD
Zaleplon—Oedema—Doxorubicin—ovarian cancer	0.000157	0.000386	CcSEcCtD
Zaleplon—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000157	0.000386	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000155	0.00038	CcSEcCtD
Zaleplon—Shock—Doxorubicin—ovarian cancer	0.000154	0.00038	CcSEcCtD
Zaleplon—Nervous system disorder—Doxorubicin—ovarian cancer	0.000154	0.000379	CcSEcCtD
Zaleplon—Insomnia—Epirubicin—ovarian cancer	0.000153	0.000377	CcSEcCtD
Zaleplon—Tachycardia—Doxorubicin—ovarian cancer	0.000153	0.000377	CcSEcCtD
Zaleplon—Skin disorder—Doxorubicin—ovarian cancer	0.000152	0.000375	CcSEcCtD
Zaleplon—Paraesthesia—Epirubicin—ovarian cancer	0.000152	0.000375	CcSEcCtD
Zaleplon—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000152	0.000373	CcSEcCtD
Zaleplon—Dyspnoea—Epirubicin—ovarian cancer	0.000151	0.000372	CcSEcCtD
Zaleplon—Somnolence—Epirubicin—ovarian cancer	0.000151	0.000371	CcSEcCtD
Zaleplon—Anorexia—Doxorubicin—ovarian cancer	0.00015	0.000368	CcSEcCtD
Zaleplon—Nausea—Docetaxel—ovarian cancer	0.000149	0.000367	CcSEcCtD
Zaleplon—Dyspepsia—Epirubicin—ovarian cancer	0.000149	0.000367	CcSEcCtD
Zaleplon—Decreased appetite—Epirubicin—ovarian cancer	0.000147	0.000363	CcSEcCtD
Zaleplon—Hypotension—Doxorubicin—ovarian cancer	0.000147	0.000361	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000146	0.00036	CcSEcCtD
Zaleplon—Pain—Epirubicin—ovarian cancer	0.000145	0.000357	CcSEcCtD
Zaleplon—Constipation—Epirubicin—ovarian cancer	0.000145	0.000357	CcSEcCtD
Zaleplon—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000143	0.000352	CcSEcCtD
Zaleplon—Insomnia—Doxorubicin—ovarian cancer	0.000142	0.000349	CcSEcCtD
Zaleplon—Paraesthesia—Doxorubicin—ovarian cancer	0.000141	0.000347	CcSEcCtD
Zaleplon—Dyspnoea—Doxorubicin—ovarian cancer	0.00014	0.000344	CcSEcCtD
Zaleplon—Feeling abnormal—Epirubicin—ovarian cancer	0.00014	0.000344	CcSEcCtD
Zaleplon—Somnolence—Doxorubicin—ovarian cancer	0.00014	0.000343	CcSEcCtD
Zaleplon—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000139	0.000341	CcSEcCtD
Zaleplon—Dyspepsia—Doxorubicin—ovarian cancer	0.000138	0.00034	CcSEcCtD
Zaleplon—Decreased appetite—Doxorubicin—ovarian cancer	0.000136	0.000336	CcSEcCtD
Zaleplon—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000135	0.000333	CcSEcCtD
Zaleplon—Urticaria—Epirubicin—ovarian cancer	0.000135	0.000331	CcSEcCtD
Zaleplon—Pain—Doxorubicin—ovarian cancer	0.000134	0.00033	CcSEcCtD
Zaleplon—Constipation—Doxorubicin—ovarian cancer	0.000134	0.00033	CcSEcCtD
Zaleplon—Abdominal pain—Epirubicin—ovarian cancer	0.000134	0.00033	CcSEcCtD
Zaleplon—Body temperature increased—Epirubicin—ovarian cancer	0.000134	0.00033	CcSEcCtD
Zaleplon—Feeling abnormal—Doxorubicin—ovarian cancer	0.000129	0.000318	CcSEcCtD
Zaleplon—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000128	0.000316	CcSEcCtD
Zaleplon—Urticaria—Doxorubicin—ovarian cancer	0.000125	0.000307	CcSEcCtD
Zaleplon—Body temperature increased—Doxorubicin—ovarian cancer	0.000124	0.000305	CcSEcCtD
Zaleplon—Abdominal pain—Doxorubicin—ovarian cancer	0.000124	0.000305	CcSEcCtD
Zaleplon—Asthenia—Epirubicin—ovarian cancer	0.000122	0.000299	CcSEcCtD
Zaleplon—Pruritus—Epirubicin—ovarian cancer	0.00012	0.000295	CcSEcCtD
Zaleplon—Asthenia—Doxorubicin—ovarian cancer	0.000113	0.000277	CcSEcCtD
Zaleplon—Dizziness—Epirubicin—ovarian cancer	0.000112	0.000276	CcSEcCtD
Zaleplon—Pruritus—Doxorubicin—ovarian cancer	0.000111	0.000273	CcSEcCtD
Zaleplon—Rash—Epirubicin—ovarian cancer	0.000107	0.000263	CcSEcCtD
Zaleplon—Dermatitis—Epirubicin—ovarian cancer	0.000107	0.000263	CcSEcCtD
Zaleplon—Headache—Epirubicin—ovarian cancer	0.000106	0.000261	CcSEcCtD
Zaleplon—Dizziness—Doxorubicin—ovarian cancer	0.000104	0.000255	CcSEcCtD
Zaleplon—Nausea—Epirubicin—ovarian cancer	0.000101	0.000248	CcSEcCtD
Zaleplon—Rash—Doxorubicin—ovarian cancer	9.89e-05	0.000243	CcSEcCtD
Zaleplon—Dermatitis—Doxorubicin—ovarian cancer	9.89e-05	0.000243	CcSEcCtD
Zaleplon—Headache—Doxorubicin—ovarian cancer	9.83e-05	0.000242	CcSEcCtD
Zaleplon—Nausea—Doxorubicin—ovarian cancer	9.32e-05	0.000229	CcSEcCtD
